One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: Results from the DiabEtic Argentina Registry (DEAR)

Cardiovascular Revascularization Medicine

Volumn 13, Issue 5, 2012, Pages 265-271

  Mieres, Juan ^a   Fernandez Pereira, Carlos ^b   Risau, Gustavo ^c   Solorzano, Leonardo ^a,b   Pauletto, Ricardo ^a,c   Rodriguez Granillo, Alfredo Matias ^d   Rubilar, Bibiana ^b   Stella, Pieter ^e   Rodriguez, Alfredo E ^a,d  

^a Sanatorio Otamendi y Miroli   (Argentina)

^b Sanatorio Las Lomas ^*  (Argentina)

^c Clinica IMA   (Argentina)

^d Cardiovascular Research Center (CECI)   (Argentina)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Diabetes mellitus; Drug eluting stent; Paclitaxel eluting balloon

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARGENTINA; ARTICLE; BARE METAL STENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE REGISTRY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; TREATMENT FAILURE;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ARGENTINA; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG-ELUTING STENTS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METALS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84866175479     PISSN: 15538389     EISSN: 18780938     Source Type: Journal    
DOI: 10.1016/j.carrev.2012.06.001     Document Type: Article

References (32)

1. Flaherty J.D., Davidson C.J. Diabetes and coronary revascularization. JAMA 2005, 293:1501-1508.
2. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
3. Jiménez-Navarro M.F., Curiel E., Hernández-García J.R., et al. Influence of diabetes mellitus on clinical outcome after percutaneous coronary revascularization. Rev Esp Cardiol 2006, 55:365-371.
4. Kip K.E., Faxon D.P., Detre K.M., et al. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996, 94:1818-1825.
5. Banning A.P., Westaby S., Morice M.C., et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol 2010, 55:1067-1075.
6. Daemen J., Kuck K.H., Macaya C., et al. Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. J Am Coll Cardiol 2008, 52:1957-1967.
7. Finn A.V., Palacios I.F., Kastrati A., Gold H.K. Drug-eluting stents for diabetes mellitus: a rush to judgment?. J Am Coll Cardiol 2005, 45:479-483.
8. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
9. Scheller B., Hehrlein C., Wet Bocksch, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006, 355:2113-2124.
10. Cortese B. The PICOLETO study and beyond. EuroIntervention 2011, 7:K53-K56.
11. Scheller B., Speck U., Abramjuk C., Bernhardt U., Bohm M., Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004, 110:810-814.
12. Fanggiday J.C., Stella P.R., Guyomi S.H., Doevendans P.A. Safety and efficacy of drug-eluting balloons in percutaneous treatment of bifurcation lesions: the DEBIUT (drug-eluting balloon in bifurcation Utrecht) registry. Catheter Cardiovasc Interv 2008, 71:629-635.
13. Perez G., Rodriguez-Granillo A.M., Mieres J., et al. New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the Camouflage registry. J Invasive Cardiol 2009, 21:378-382.
14. Rodriguez A.E., Granada J.F., Rodriguez-Alemparte M., et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006, 47:1522-1529.
15. Rodriguez A.E., Grinfeld L., Fernandez-Pereira C., et al. Revascularization strategies of coronary multiple vessel disease in the drug eluting stent era: one year follow-up results of the ERACI III Trial. EuroIntervention 2006, 2:53-60.
16. Rodriguez A.E., Maree A., Tarragona S., et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention 2009, 5:255-264.
17. Rodriguez A.E., Vigo C.F., Delacasa A., et al. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: the EUCATAX trial. Catheter Cardiovasc Interv 2011, 77:335-342.
18. Mauri L., Hsieh W.H., Massaro J.M., et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007, 356:1020-1029.
19. Rodriguez A.E., Mieres J., Fernandez-Pereira C., et al. Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol 2006, 47:205-207.
20. Posa A., Nyolzas N., Hemetsberger R., et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel- eluting DIOR-balloon in porcine coronary arteries. Catheter Cardiovasc Interv 2010, 76:395-403.
21. Rodriguez A., Ayala F., Bernardi V., et al. Optimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. J Am Coll Cardiol 1998, 32:1351-1357.
22. Rodriguez A.E., Santaera O., Larribau M., et al. Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation 1995, 91:1397-1402.
23. Caixeta A., Leon M.B., Lansky A.J., et al. 5-year clinical outcomes after sirolimus-eluting stent implantation insights from a patient-level pooled analysis of 4 randomized trials comparing sirolimus-eluting stents with bare-metal stents. J Am Coll Cardiol 2009, 54:894-902.
24. Lee M.S., Yang T., Dhoot J., Iqbal Z., Liao H. Meta-analysis of studies comparing coronary artery bypass grafting with drug-eluting stenting in patients with diabetes mellitus and multivessel coronary artery disease. Am J Cardiol 2010, 105:1540-1544.
25. Bischof M., Briel M., Bucher H.C., Nordmann A. Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. Value Health 2009, 12:649-656.
26. Stettler C., Allemann S., Wandel S., et al. Drug eluting and bare metal stents in people with and without diabetes: collaborative network meta-analysis.TAXUS metanalisis. BMJ 2008, 337:a1331. 10.1136/bmj.a1331.
27. Caixeta A., Lansky A.J., Serruys P.W., et al. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents a pooled analysis from the SPIRIT II (a clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions) and SPIRIT III (a clinical evaluation of the investigational device XIENCE V everolimus eluting coronary stent system [EECSS] in the treatment of subjects with de novo native coronary artery lesions) randomized trials. JACC Cardiovasc Interv 2010 Dec, 3(12):1220-1228.
28. Stone G.W., Kedhi E., Kereiakes D.J., et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011, 124:893-900.
29. Kufner S., de Waha A., Tomai F., et al. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am Heart J 2011, 162(4):740-747.
30. Kastrati A., Massberg S., Ndrepepa G. Is diabetes the achilles' heel of limus-eluting stents?. Circulation 2011, 124(8):869-872.
31. Mohad Ali R., Degenhardt R., Zambahari R., et al. Paclitaxel-eluting balloon angioplasty and cobalt-chromiun stents versus conventional angioplasty and paclitaxel-eluting stents in treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention 2011, 7:K83-K92.
32. West N.E., Ruygrok P.N., Disco C.M., et al. Clinical and angiographic predictors of restenosis after stent deployment in diabetic patients. Circulation 2004, 109:867-873.